Mark H. Rachesky, MD, an Executive Officer at MHR Sun III, is an individual and angel investor with a keen interest. See sector focus and contact routes.
Mark H. Rachesky, MD, an Executive Officer at MHR Sun III, is an individual and angel investor with a keen interest in the advancement of medical science, particularly within oncology. His investment focus aligns with companies dedicated to pioneering novel cancer therapies. He supports organizations that prioritize the discovery, development, and investigation of innovative and potentially life-changing treatments. Dr. Rachesky is particularly drawn to companies addressing disease areas with high unmet medical needs in oncology, recognizing the critical importance of bringing new solutions to patients. His investment philosophy emphasizes supporting leaders in cutting-edge technologies, such as oral Selective Inhibitor of Nuclear Export (SINE) technology, which holds significant promise in the fight against cancer.
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in New York when building a target list.
Investors like Mark H. Rachesky, MD · Full investor directory · Investor access · Company funding database